Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study

Hepatology

Volumn 64, Issue 6, 2016, Pages 1893-1899

  Tapper, Elliot B ^a   Bacon, Bruce R ^b   Curry, Michael P ^a   Dieterich, Douglas T ^c   Flamm, Steven L ^d   Guest, Lauren E ^e   Kowdley, Kris V ^f   Lee, Yoori ^e   Tsai, Naoky C ^g   Younossi, Zobair M ^h   Afdhal, Nezam H ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e Trio Health Analytics   (United States)

^f SWEDISH MEDICAL CENTER   (United States)

^g QUEEN S MEDICAL CENTER   (United States)

^h INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; LEDIPASVIR; OMEPRAZOLE; RIBAVIRIN; SOFOSBUVIR; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; PROTON PUMP INHIBITOR;

ADULT; ARTICLE; BODY MASS; CHRONIC HEPATITIS C; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DIABETES MELLITUS; DRUG MEGADOSE; FEMALE; HEPATITIS C VIRUS SUBTYPE 1A; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RACE; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SUSTAINED VIROLOGICAL RESPONSE; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD; DRUG EFFECTS; DRUG INTERACTION; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED;

ANTIVIRAL AGENTS; BENZIMIDAZOLES; COHORT STUDIES; DRUG INTERACTIONS; FEMALE; FLUORENES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; RIBAVIRIN; SOFOSBUVIR; TREATMENT OUTCOME;

EID: 84994621386     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28782     Document Type: Article

References (18)

1. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483–1493.
2. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889–1898.
3. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS, et al.; SOLAR-1 Investigators. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015;149:649–659.
4. Curry MP, Forns X, Chung RT, Terrault NA, Brown R, Fenkel JM, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 2015;148:100–107. e1.
5. Forns X, Charlton M, Denning J, McHutchison JG, Symonds WT, Brainard D, et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology 2015;61:1485–1494.
6. Younossi ZM, Stepanova M, Marcellin P, Afdhal N, Kowdley KV, Zeuzem S, Hunt SL. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1,-2, and-3 clinical trials. Hepatology 2015;61:1798–1808.
7. Chahal HS, Marseille EA, Tice JA, Pearson SD, Ollendorf DA, Fox RK, Kahn JG. Cost-effectiveness of early treatment of hepatitis C Virus Genotype 1 by stage of liver fibrosis in a US treatment-naive population. JAMA Intern Med 2016;176:65–73.
8. Chhatwal J, Kanwal F, Roberts MS, Dunn MA. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med 2015;162:397–406.
9. Younossi ZM, Singer ME, Mir HM, Henry L, Hunt S. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. J Hepatol 2014;60:530–537.
10. Linas BP, Barter DM, Morgan JR, Pho MT, Leff JA, Schackman BR, et al. The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med 2015;162:619–629.
11. Najafzadeh M, Andersson K, Shrank WH, Krumme AA, Matlin OS, Brennan T, et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med 2015;162:407–419.
12. HARVONI (ledipasvir and sofosbuvir) tablets [package insert]. Foster City, CA: Gilead Sciences.
13. Terrault N, Zeuzem S, Di Bisceglie AM, Lim JK, Pockros PJ, Frazier LM, et al. Treatment outcomes with 8, 12 and 24 week regimens of ledipasvir/sofosbuvir for the treatment of hepatitis C infection: analysis of a multicenter prospective, observational study. Hepatology 2015;62:256A.
14. Firth D. Bias reduction of maximum likelihood estimates. Biometrika 1993;80:27–38.
15. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879–1888.
16. Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015;373:705–713.
17. Kanwal F, El-Serag HB. Hepatitis C virus treatment: the unyielding chasm between efficacy and effectiveness. Clin Gastroenterol Hepatol 2014;12:1381–1383.
18. Miner P, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003;98:2616–2620.